Zura Bio Limited (NASDAQ:ZURA) Short Interest Down 51.8% in April

Zura Bio Limited (NASDAQ:ZURA - Get Free Report) saw a large drop in short interest in April. As of April 15th, there was short interest totalling 2,590,000 shares, a drop of 51.8% from the March 31st total of 5,370,000 shares. Currently, 5.6% of the company's stock are sold short. Based on an average trading volume of 373,200 shares, the short-interest ratio is presently 6.9 days.

Institutional Trading of Zura Bio

Several hedge funds and other institutional investors have recently modified their holdings of ZURA. Geode Capital Management LLC raised its holdings in Zura Bio by 70.6% in the 3rd quarter. Geode Capital Management LLC now owns 912,625 shares of the company's stock valued at $3,706,000 after acquiring an additional 377,545 shares during the period. Barclays PLC grew its position in shares of Zura Bio by 777.1% in the third quarter. Barclays PLC now owns 64,061 shares of the company's stock valued at $260,000 after purchasing an additional 56,757 shares during the last quarter. Rhumbline Advisers increased its stake in shares of Zura Bio by 37.3% during the fourth quarter. Rhumbline Advisers now owns 37,657 shares of the company's stock worth $94,000 after purchasing an additional 10,231 shares during the period. State Street Corp lifted its holdings in Zura Bio by 47.5% during the 3rd quarter. State Street Corp now owns 395,059 shares of the company's stock worth $1,604,000 after purchasing an additional 127,300 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in Zura Bio by 12,060.8% in the 4th quarter. JPMorgan Chase & Co. now owns 2,633,185 shares of the company's stock valued at $6,583,000 after purchasing an additional 2,611,532 shares during the period. Institutional investors own 61.14% of the company's stock.

Analyst Ratings Changes

Several research firms recently issued reports on ZURA. HC Wainwright reiterated a "buy" rating on shares of Zura Bio in a report on Thursday, April 3rd. Oppenheimer reissued an "outperform" rating and issued a $19.00 price objective (down previously from $20.00) on shares of Zura Bio in a report on Wednesday, March 26th. Chardan Capital lowered their target price on shares of Zura Bio from $12.00 to $10.00 and set a "buy" rating on the stock in a report on Wednesday, March 26th. Finally, Guggenheim reaffirmed a "buy" rating and set a $15.00 price target on shares of Zura Bio in a research report on Wednesday, March 26th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $14.67.

Zura Bio Stock Down 4.5 %

Shares of NASDAQ ZURA traded down $0.07 during midday trading on Thursday, hitting $1.47. 303,306 shares of the company's stock were exchanged, compared to its average volume of 387,013. The firm has a market capitalization of $100.51 million, a PE ratio of -2.77 and a beta of 0.08. Zura Bio has a 12 month low of $0.97 and a 12 month high of $6.35. The company's 50 day moving average price is $1.27 and its 200 day moving average price is $2.27.

Zura Bio (NASDAQ:ZURA - Get Free Report) last released its quarterly earnings data on Tuesday, March 25th. The company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.09. The company had revenue of $0.00 million for the quarter. On average, equities research analysts anticipate that Zura Bio will post -0.65 EPS for the current year.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.